While many prognostic signatures have been identified, all of them predict poor patient outcome either in luminal ER+ or in basal ER- tumors [10], thus requiring the context (microenvironment) of the particular tumor type to be predictive, they are agnostic of the existence of a common CSC population for luminal and basal breast cancer patients. The gene discussed is ESR1; the disease is breast cancer.